AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A method of inactivating enveloped viruses in a ~~contaminating a viral~~ preparation ~~predominantly~~ containing adenoviruses in which a sufficient quantity of ~~a~~ solvent tri-n-butyl phosphate (TNBP) of between 0.1% and 0.6% (volume/volume) is introduced into the said viral preparation and the said solvent is allowed to act at a temperature between +4°C ~~-5°C~~ to +37°C ~~+50°C~~, at a pH of between 6.5 to 8.5 ~~5 to 9~~ for a period which is sufficiently long to significantly reduce the quantity of enveloped viruses present in the said viral preparation, wherein said method of inactivation is capable of preserving at least 80% of the infectious activity of said adenoviruses.

Claim 2. – 4. (Canceled)

Claim 5. (Previously Presented) The method of inactivating enveloped viruses according to Claim 1, the method is carried out in the presence of a solubilizing agent.

Claim 6. (Previously Presented) The method of inactivating enveloped viruses according to Claim 5, wherein the solubilizing agent is a Tween.

Claim 7. (Previously Presented) The method of inactivating enveloped viruses according to Claim 5, wherein the quantity of solubilizing agent introduced into the viral preparation is between 0.001% and 10%.

Claim 8. – 9. (Canceled)

Claim 10. (Previously Presented) The method of inactivating enveloped viruses according to Claim 1, wherein the solvent is allowed to act for a period of between 15 minutes and 24 hours.

Claim 11. (Previously Presented) The method of inactivating enveloped viruses according to Claim 1, wherein the method is carried out with stirring.

Claim 12. (Previously Presented) The method of inactivating enveloped viruses according to Claim 1, wherein the said method is carried out under conductivity conditions of between 5 and 500 mS/cm.

Claims 13-17. (Canceled)

Claim 18. (Currently Amended) The method of inactivating enveloped viruses of claim 1 ~~17~~, wherein the quantity of TNBP introduced into the said viral preparation is in the region of 0.3% (volume/volume).

Claim 19. (Previously Presented) The method of inactivating enveloped viruses of claim 7, wherein the quantity of solubilizing agent introduced into the said viral preparation is between 0.01% and 5% (volume/volume).

Claim 20. (Previously Presented) The method of inactivating enveloped viruses of claim 19, wherein the quantity of solubilizing agent introduced into the said viral preparation is between 0.1% and 2% (volume/volume).

Claim 21. (Previously Presented) The method of inactivating enveloped viruses of claim 20, wherein the solubilizing agent introduced into the said viral preparation is Tween 80.

Claim 22. (Currently Amended) The method of inactivating enveloped viruses of claim 1 ~~8~~, wherein the temperature is between +15°C and +25°C.

Claim 23. (Currently Amended) The method of inactivating enveloped viruses of claim 1 ~~9~~, wherein the pH is 8.5.

Claim 24. (Previously Presented) The method of inactivating enveloped viruses of claim 10, wherein the period of time is of between 1 hour and 5 hours.

Claim 25. (Previously Presented) The method of inactivating enveloped viruses of claim 12, wherein the conductivity conditions are between 10 and 100 mS/cm.

Claim 26. (Previously Presented) The method of inactivating enveloped viruses of claim 1, wherein TNBP at a final concentration of between 0.1% and 0.6% (volume/volume) and Tween 80 at a final concentration of between 0.5% and 2% (volume/volume) are introduced into said viral preparation, said TNBP and said Tween 80 are allowed to act at room temperature at a pH of 8.5 for a period of time between 1 hour and 5 hours, wherein at least 80% of the infectious activity of said adenoviruses is preserved.

Claim 27. (Previously Presented) The method of inactivating enveloped viruses of claim 1, wherein said adenovirus is recombinant.

Claim 28. (Previously Presented) The method of inactivating enveloped viruses of claim 1, wherein said adenovirus is replication-defective.

Claims 29-31. (Cancelled)